Amryt Pharma (Amryt Pharma) Other Long Term Assets : $1.7 Mil (As of Sep. 2022)

View and export this data going back to 2019. Start your Free Trial

What is Amryt Pharma Other Long Term Assets?

Amryt Pharma's other long-term assets for the quarter that ended in Sep. 2022 was $1.7 Mil.

Amryt Pharma's quarterly other long-term assets declined from Mar. 2022 ($1.8 Mil) to Jun. 2022 ($1.8 Mil) but then stayed the same from Jun. 2022 ($1.8 Mil) to Sep. 2022 ($1.7 Mil).

Amryt Pharma's annual other long-term assets declined from Dec. 2019 ($1.9 Mil) to Dec. 2020 ($1.5 Mil) but then increased from Dec. 2020 ($1.5 Mil) to Dec. 2021 ($1.9 Mil).

Amryt Pharma Other Long Term Assets Historical Data

The historical data trend for Amryt Pharma's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amryt Pharma Other Long Term Assets Chart

Amryt Pharma Annual Data

Trend

Mar12

Mar13

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Other Long Term Assets

Get a 7-Day Free Trial

0.15

1.87

1.54

1.88

Amryt Pharma Quarterly Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Other Long Term Assets	Get a 7-Day Free Trial															1.65	1.88	1.85	1.77	1.75

Amryt Pharma Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Amryt Pharma (Amryt Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amryt Pharma PLC (NAS:AMYT) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

N/A

Address

196 High Road, Dept 920A, Wood Green, London, GBR, N22 8HH

Website

http://www.amrytpharma.com

Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).